<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2017-12-138-143</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-2045</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ТРОМБОЗЫ И ТРОМБОЭМБОЛИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>THROMBOSIS AND THROMBOEMBOLISM</subject></subj-group></article-categories><title-group><article-title>ВОЗОБНОВЛЕНИЕ АНТИТРОМБОТИЧЕСКОЙ ТЕРАПИИ У БОЛЬНЫХ ИБС ПОСЛЕ ЭПИЗОДА КРОВОТЕЧЕНИЯ</article-title><trans-title-group xml:lang="en"><trans-title>RESTORATION OF ANTITHROMBOTIC THERAPY IN IBS PATIENTS AFTER EPISODE OF BLEEDING</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сумароков</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Sumarokov</surname><given-names>A. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н.</p></bio><bio xml:lang="en"><p>PhD in medicine</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Доценко</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dotsenko</surname><given-names>Y. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н. </p></bio><bio xml:lang="en"><p>PhD</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Институт клинической кардиологии им. А.Л. Мясникова Российского кардиологического научно-производственного комплекса Минздрава России,</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Myasnikov Institute of Clinical Cardiology FSBI RCNIC of the MInistry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>04</day><month>11</month><year>2017</year></pub-date><volume>0</volume><issue>12</issue><fpage>138</fpage><lpage>143</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сумароков А.Б., Доценко Ю.В., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Сумароков А.Б., Доценко Ю.В.</copyright-holder><copyright-holder xml:lang="en">Sumarokov A.B., Dotsenko Y.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/2045">https://www.med-sovet.pro/jour/article/view/2045</self-uri><abstract><p>Лечение антитромботическими препаратами является балансированием между риском появления кровоточивости, вплоть до фатального кровотечения, и риском непредотвращенного тромбоза. В случае состоявшегося кровотечения проблемы сохранения баланса гемостаза многократно возрастают, что требует от врача четкого понимания и предвидения развития возможных осложнений. Полный отказ от антитромботической терапии (АТТ) сразу после кровотечения может привести к реальной угрозе тромбоза через несколько дней после отмены. Обсуждена тактика возобновления АТТ у больных ИБС после кровотечения: приведены основные классификации кровотечений, применяемые при сердечно-сосудистых заболеваниях (ССЗ), разобраны шкалы риска кровотечений и тромбоза в свете последних (ноябрь 2016 г.) рекомендаций экспертов Европейского общества кардиологов (ЕОК).</p><sec><title> </title><p> </p></sec><sec><title> </title><p> </p></sec></abstract><trans-abstract xml:lang="en"><p>Rational balance between risks of bleeding and risks of thrombosis is cornerstone of modern antithrombotic therapy. Regulation of haemostasis has no any physical signs. In a case of bleeding careful management is of great importance. Abrupt discontinuation of antithrombotic therapy is associated with some degree of thrombosis risk. Problems of re-initiation of antithrombotic therapy in CAD patients after bleeding are discussed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ИБС</kwd><kwd>антитромботическая терапия</kwd><kwd>кровотечение</kwd><kwd>возобновление терапии</kwd><kwd>риски тромбоза и рецидива кровотечения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hemorrhage in CAD patients during antithrombotic therapy</kwd><kwd>resumption of therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Roy T, Bonello L, Torguson R, de Labriolle A, Lemesle G, Slottow TLP, Steinberg DH, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waxman R Impact of Nuisanse” Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation. Am J Cardiol, 2008, 102 (12): 1614–1617.</mixed-citation><mixed-citation xml:lang="en">Roy T, Bonello L, Torguson R, de Labriolle A, Lemesle G, Slottow TLP, Steinberg DH, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waxman R Impact of Nuisanse” Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation. Am J Cardiol, 2008, 102 (12): 1614–1617.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Сумароков А.Б., Бурячковская Л.И., Учитель И.А. Кровотечения у больных ишемической болезнью сердца при проведении терапии антиагрегантами. CardioСоматика, 2011, 2(3): 29–34.</mixed-citation><mixed-citation xml:lang="en">Сумароков А.Б., Бурячковская Л.И., Учитель И.А. Кровотечения у больных ишемической болезнью сердца при проведении терапии антиагрегантами. CardioСоматика, 2011, 2(3): 29–34.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ben-Dor I, Torguson R, Scheinowitz M, Li Y, Delhaye C, Wakabayashi K, Maluenda G, Syed AI, Collins SD, Gonsales MA, Gaglia M A Jr, Xue Z, Kaneshige K, Satler LF, Kent KM, Pichard AD, Waxman R. Incidence, correlates and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am Heart J, 2010, 159: 871-875.</mixed-citation><mixed-citation xml:lang="en">Ben-Dor I, Torguson R, Scheinowitz M, Li Y, Delhaye C, Wakabayashi K, Maluenda G, Syed AI, Collins SD, Gonsales MA, Gaglia M A Jr, Xue Z, Kaneshige K, Satler LF, Kent KM, Pichard AD, Waxman R. Incidence, correlates and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am Heart J, 2010, 159: 871-875.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ducrocq G, Wallace J, Baron G, Ravard Ph, Alberts MJ, Wilson PWF, Ohman EM, Brennan DM, D`Agostino RB, Bhatt DL, Steg PhG on behalf of the REACH Investigators, Risk score to predict serious bleeding in stable outpatients with or risk of atherothrombosis. Eur Heart J, 2010, 31: 1257-1265.</mixed-citation><mixed-citation xml:lang="en">Ducrocq G, Wallace J, Baron G, Ravard Ph, Alberts MJ, Wilson PWF, Ohman EM, Brennan DM, D`Agostino RB, Bhatt DL, Steg PhG on behalf of the REACH Investigators, Risk score to predict serious bleeding in stable outpatients with or risk of atherothrombosis. Eur Heart J, 2010, 31: 1257-1265.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Rao SV, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in Myocardial Infarction (TIMI) Trial phase-I: hemorrhagic manifestations and changes in plasma fibrino-gen system and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. JACC, 1988, 11(1): 1-11.</mixed-citation><mixed-citation xml:lang="en">Rao SV, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in Myocardial Infarction (TIMI) Trial phase-I: hemorrhagic manifestations and changes in plasma fibrino-gen system and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. JACC, 1988, 11(1): 1-11.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">GUSTO Investigators. An international rand-omized trial comparing four thrombolytic strategies for acute myocardial infarction. NEJM, 1993, 329(10): 673-682.</mixed-citation><mixed-citation xml:lang="en">GUSTO Investigators. An international rand-omized trial comparing four thrombolytic strategies for acute myocardial infarction. NEJM, 1993, 329(10): 673-682.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Serebruany VL, Atar D. Assesment of blleding events in clinical trials – proposed of a new classification. Am J Cardiol, 2007, 99(2): 288-290.</mixed-citation><mixed-citation xml:lang="en">Serebruany VL, Atar D. Assesment of blleding events in clinical trials – proposed of a new classification. Am J Cardiol, 2007, 99(2): 288-290.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Rao SV, Eikelboom J, Steg G, Lincoff AM, Weintraub WS, Bassand J-P, Rao AK, Gibson CM, Petersen JL, Mehran R, Manoukian SV, Charrigo R, Lee KL, Moscucci M, Harrington RA, on behalf of the Academic Bleeding Consensus Multidisciplinary Working Group, Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A prorosal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. Am Heart J, 2009, 158: 881-886.</mixed-citation><mixed-citation xml:lang="en">Rao SV, Eikelboom J, Steg G, Lincoff AM, Weintraub WS, Bassand J-P, Rao AK, Gibson CM, Petersen JL, Mehran R, Manoukian SV, Charrigo R, Lee KL, Moscucci M, Harrington RA, on behalf of the Academic Bleeding Consensus Multidisciplinary Working Group, Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A prorosal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. Am Heart J, 2009, 158: 881-886.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mehran R, Rao SV, Bhatt DL, GibsonCM, Caixeta A, Eikelboom J, Kaul S, Wiwiott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials a consensus report from the bleeding academic research consortium. Circulation, 2011, 123(23): 2736-2747.</mixed-citation><mixed-citation xml:lang="en">Mehran R, Rao SV, Bhatt DL, GibsonCM, Caixeta A, Eikelboom J, Kaul S, Wiwiott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials a consensus report from the bleeding academic research consortium. Circulation, 2011, 123(23): 2736-2747.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Forest JA, Finlayson ND, Shearman DJ, Endoscopy in gastrointestinal bleeding. Lancet, 1974, 2: 394-397.</mixed-citation><mixed-citation xml:lang="en">Forest JA, Finlayson ND, Shearman DJ, Endoscopy in gastrointestinal bleeding. Lancet, 1974, 2: 394-397.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Waxman R, Definition, Incidence, Correlates and Clinical Impact of “Nuisance” bleeding in Patients Undergoing Drug-Eluting Stent Implantation. Am J Cardiol, 2009, 104(4): 30-33.</mixed-citation><mixed-citation xml:lang="en">Waxman R, Definition, Incidence, Correlates and Clinical Impact of “Nuisance” bleeding in Patients Undergoing Drug-Eluting Stent Implantation. Am J Cardiol, 2009, 104(4): 30-33.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH, Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Mayor Bleeding in patients With Atrial Fibrillation: The Euro Heart Survey. Chest, 2010, 138(5): 1093-1100.</mixed-citation><mixed-citation xml:lang="en">Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH, Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Mayor Bleeding in patients With Atrial Fibrillation: The Euro Heart Survey. Chest, 2010, 138(5): 1093-1100.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Subherwal S, Bach R, Chen A et al. Baseline Risk of Major Bleeding in Non ST-Segment Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early Implementation of the ACC/AHA guidelines) Bleeding Score. Circulation, 2009, 119: 1873-1882.</mixed-citation><mixed-citation xml:lang="en">Subherwal S, Bach R, Chen A et al. Baseline Risk of Major Bleeding in Non ST-Segment Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early Implementation of the ACC/AHA guidelines) Bleeding Score. Circulation, 2009, 119: 1873-1882.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Halvorsen S, Storey RF, Rocca B, Sibbing D, ten Berg J, Grove EL, Weiss ThW, Collet J-P, Andreotti F, Gulba DC, Lip GYH, Husted S, Vilahur G, Morais J, Verheught FWA, Lanas A, Salman R, Steg PG, Huber K on behalf of ESC Working Group on Thrombosis, Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J, 2016, 11: 1-11.</mixed-citation><mixed-citation xml:lang="en">Halvorsen S, Storey RF, Rocca B, Sibbing D, ten Berg J, Grove EL, Weiss ThW, Collet J-P, Andreotti F, Gulba DC, Lip GYH, Husted S, Vilahur G, Morais J, Verheught FWA, Lanas A, Salman R, Steg PG, Huber K on behalf of ESC Working Group on Thrombosis, Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J, 2016, 11: 1-11.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Levine GN (Chair) et al. 2016 ACCF/AHA/SCAI Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practical Guidelines. JACC, 2016, 68(10): 1082-1115.</mixed-citation><mixed-citation xml:lang="en">Levine GN (Chair) et al. 2016 ACCF/AHA/SCAI Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practical Guidelines. JACC, 2016, 68(10): 1082-1115.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Veich AM, Vanbiervliet G, Gershlick AH, Boustiere Ch, Baglin TP, Smith L-A, Radaelly F, Knight E, Gralnek IM, Hassan C, Dumonceau J-M, Endoscopy in patients on antiplatelet therapy, including oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endosopy, 2016, 48: 1-18.</mixed-citation><mixed-citation xml:lang="en">Veich AM, Vanbiervliet G, Gershlick AH, Boustiere Ch, Baglin TP, Smith L-A, Radaelly F, Knight E, Gralnek IM, Hassan C, Dumonceau J-M, Endoscopy in patients on antiplatelet therapy, including oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endosopy, 2016, 48: 1-18.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VKS, Wong VWS, Chan FKL. Continuation of low dose aspirin therapy in peptic ulcers bleeding. A randomized trial. Ann Intern Med, 2010, 152(1): 1-9.</mixed-citation><mixed-citation xml:lang="en">Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VKS, Wong VWS, Chan FKL. Continuation of low dose aspirin therapy in peptic ulcers bleeding. A randomized trial. Ann Intern Med, 2010, 152(1): 1-9.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chai-Adisaksopha C, Hillis C, Monreal M, Witt DM, Growther M. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta - analysis. Thromb Haemostasis, 2015, 114: 819-825.</mixed-citation><mixed-citation xml:lang="en">Chai-Adisaksopha C, Hillis C, Monreal M, Witt DM, Growther M. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta - analysis. Thromb Haemostasis, 2015, 114: 819-825.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Staerk L, Lip GYH, Olesen JB, Fosbol EL, Pallisgaarg JL, Bonde AN, Gunlund A, Lindhardt TB, Hansen ML, Torp-Petersen C, Gislason GH. Stroke and recurrent haemorrage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ, 2015, 351: 5876.</mixed-citation><mixed-citation xml:lang="en">Staerk L, Lip GYH, Olesen JB, Fosbol EL, Pallisgaarg JL, Bonde AN, Gunlund A, Lindhardt TB, Hansen ML, Torp-Petersen C, Gislason GH. Stroke and recurrent haemorrage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ, 2015, 351: 5876.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Qureshi W, Mittal S, Patsias I, Garicapati K, Kuchiridi A, Cheema G, Elbatta M, Alirhayim Z, Khalid F. Restarting anticoagulation and outcomes after mayor gastrointestinal bleeding in atrial fibrillation. Am J Cardiol, 2014, 113(4): 662-668.</mixed-citation><mixed-citation xml:lang="en">Qureshi W, Mittal S, Patsias I, Garicapati K, Kuchiridi A, Cheema G, Elbatta M, Alirhayim Z, Khalid F. Restarting anticoagulation and outcomes after mayor gastrointestinal bleeding in atrial fibrillation. Am J Cardiol, 2014, 113(4): 662-668.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Thal S, Moukabary T, Boyella R, Shanmugasundaram M, Pierce MK, Thai H et al. The relationship between warfarin, aspirin, and clopidogrel continuation in the peri-procedual period and the incidence of hematoma formation after device implantation. Pacing Clin Electrophysiol, 2010, 33(4): 385-388.</mixed-citation><mixed-citation xml:lang="en">Thal S, Moukabary T, Boyella R, Shanmugasundaram M, Pierce MK, Thai H et al. The relationship between warfarin, aspirin, and clopidogrel continuation in the peri-procedual period and the incidence of hematoma formation after device implantation. Pacing Clin Electrophysiol, 2010, 33(4): 385-388.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
